In the context of proliferation, SYK promotes the activation of the lipid-modifying kinase phosphoinositide 3 kinase (PI3K) and its downstream mediator protein kinase B (PKB). In addition ...

Celcuity's gedatolisib, a dual PI3K/mTOR inhibitor, shows promise in Phase 3 breast cancer trials. Click here to read an ...

Our laboratory is dedicated to understanding the consequences of activation of these pathways and to using this information to develop mechanism-based therapeutic strategies. The laboratory is ...

They also discovered that the PI3K complex, an autophagy-related protein, is essential for this formation process. The ...

The current PI3K 3C inhibitors in use in advanced breast cancer are alpelisib and inavolisib. Capivasertib is an AKT inhibitor, which is also used in PI3K 3C mutated breast cancer. So these are ...

Aspirin reduced colorectal cancer recurrence risk by 50% in patients with PIK3CA mutations over three years. Mutations in the PI3K pathway predict aspirin response, broadening its use to more patients ...